Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Mona Tomaschko Clear advanced filters

  • Analyses of in vivo models, cell lines and patient-derived samples show that apolipoprotein B mRNA-editing catalytic subunit 3B (APOBEC3B) not only restrains lung tumor initiation but also that its upregulation is associated with resistance to targeted therapies. This study highlights the complex and context-dependent role of APOBEC3B in lung cancer.

    • Deborah R. Caswell
    • Philippe Gui
    • Charles Swanton
    ResearchOpen Access
    Nature Genetics
    Volume: 56, P: 60-73

  • GDP-bound form of KRASG12C inhibitors have been approved for the treatment of patients with advanced KRASG12C mutant non-small cell lung cancer (NSCLC), however resistance to these drugs is often observed. Here the authors report that combining a GTP-bound RAS G12C-selective inhibitor with SHP2 inhibition can sensitize lung tumours to immune checkpoint blockade.

    • Panayiotis Anastasiou
    • Christopher Moore
    • Julian Downward
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-17